Want to join the conversation?
$BCR's 3Q15 sales from surgical graft were up 4% in 3Q15. The Endovascular business sales grew 18%, excluding the royalty payment from Gore. Within the Endovascular business, biopsy products climbed 14%, driven by healthy growth across the U.S. and even better performance internationally.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!